Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2021-02-04 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
独立董事关于第四届董事会第十次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on the company's 2021 restricted stock incentive plan and its assessment management measures. It references compliance with regulatory rules and company governance but does not contain financial statements or quarterly/yearly financial results. It is a formal opinion related to board matters and governance rather than a financial report or announcement of voting results. The content aligns with Board/Management Information (MANG) as it concerns board-level decisions and opinions on management incentive plans. The document length is short (2108 characters), and it is not an announcement of a report publication or a certification. Therefore, the best classification is MANG with high confidence.
2021-02-04 Chinese
关于董事兼副总经理减持计划实施完毕的公告
Director's Dealing Classification · 100% confidence The document is an announcement regarding the completion of a share reduction plan by a company director and vice general manager. It details the shareholding changes, dates, and compliance with relevant laws and regulations. The content focuses on insider share transactions by a company director, including specific share quantities and percentages before and after the reduction. There is no financial performance data, earnings information, or report publication mentioned. The document fits the definition of a Director's Dealing report, which covers personal share transactions by company directors and executives (insider trades). The document length is short and it is a direct announcement of insider share transactions, not a full financial report or other category.
2021-01-15 Chinese
关于公司HA树脂血液灌流的卫生经济学研究成果摘要的自愿性信息披露公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by the company about the summary of a health economic study related to their HA resin blood perfusion product. It includes a summary of the study's purpose, methods, results, and potential impact on the company. The document is relatively short (1385 characters) and does not contain detailed financial statements or comprehensive financial data. It is an informational announcement about research findings rather than a formal financial report or regulatory filing. There is no indication that this is an annual report, interim report, earnings release, or any other detailed financial or governance document. It also does not fit into categories like management changes, voting results, or legal proceedings. Given the nature of the content and the voluntary disclosure format, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous announcements that do not fit other specific categories.
2021-01-11 Chinese
2020年年度业绩预增公告
Earnings Release Classification · 95% confidence The document is a 2020 annual performance forecast announcement by the company, indicating expected net profit growth for the full year 2020. It explicitly states that the forecast is unaudited and preliminary, and that detailed audited financial data will be disclosed in the 2020 annual report. The document is short (810 characters) and serves as a performance preview rather than a full financial report. It does not contain actual financial statements or comprehensive analysis, only an earnings outlook. Therefore, it fits the definition of an Earnings Release (ER) as an initial announcement of periodical financial results highlighting key figures and expectations. FY 2020
2021-01-06 Chinese
关于使用部分闲置自有资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by the company regarding the use of part of its idle funds for cash management. It details the board meeting resolution, investment purpose, amount, risk analysis, and approvals by independent directors and the supervisory board. The document is relatively short (2274 characters) and does not contain financial statements or detailed financial data. It is a regulatory announcement about a financing/capital management decision rather than a full financial report or earnings release. Therefore, it fits best under Capital/Financing Update (CAP).
2021-01-04 Chinese
第四届监事会第九次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of the company regarding the approval of a proposal to use idle funds for cash management. It includes details about the meeting, attendance, and voting results. It references a related announcement published on the official disclosure website. The document is short (774 characters) and primarily serves as an official announcement of a board decision rather than a full report or detailed financial disclosure. It does not contain financial statements or detailed management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous official announcements that do not fit other specific categories.
2021-01-04 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.